Haleon PLC ( (GB:HLN) ) just unveiled an update.
Haleon PLC announced the purchase of 826,862 ordinary shares for cancellation as part of its share buyback programme initiated on 28 March 2025. This transaction impacts the company’s share capital, reducing the number of ordinary shares with voting rights to 9,032,421,345, which stakeholders can use to assess their interests under the FCA’s Disclosure Guidance and Transparency Rules.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. Its product portfolio includes Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals and Supplements (VMS). The company is known for its trusted brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum.
YTD Price Performance: 2.86%
Average Trading Volume: 27,917,289
Technical Sentiment Signal: Strong Sell
Current Market Cap: £35.41B
See more data about HLN stock on TipRanks’ Stock Analysis page.